EFFECT OF GENISTEIN AND OXALIPLATIN ON CANCER STEM CELLS IN ORAL SQUAMOUS CELL CARCINOMA: AN EXPERIMENTAL STUDY
Hussein, A., El-Sheikh, S., Darwish, Z., Hussein, K., Gaafar, A. (2018). EFFECT OF GENISTEIN AND OXALIPLATIN ON CANCER STEM CELLS IN ORAL SQUAMOUS CELL CARCINOMA: AN EXPERIMENTAL STUDY. EKB Journal Management System, 43(1), 117-123. doi: 10.21608/adjalexu.2018.57611
Ahmed M. Hussein; Sahar M. El-Sheikh; Zeinab E. Darwish; Khaled A. Hussein; Ashraf I. Gaafar. "EFFECT OF GENISTEIN AND OXALIPLATIN ON CANCER STEM CELLS IN ORAL SQUAMOUS CELL CARCINOMA: AN EXPERIMENTAL STUDY". EKB Journal Management System, 43, 1, 2018, 117-123. doi: 10.21608/adjalexu.2018.57611
Hussein, A., El-Sheikh, S., Darwish, Z., Hussein, K., Gaafar, A. (2018). 'EFFECT OF GENISTEIN AND OXALIPLATIN ON CANCER STEM CELLS IN ORAL SQUAMOUS CELL CARCINOMA: AN EXPERIMENTAL STUDY', EKB Journal Management System, 43(1), pp. 117-123. doi: 10.21608/adjalexu.2018.57611
Hussein, A., El-Sheikh, S., Darwish, Z., Hussein, K., Gaafar, A. EFFECT OF GENISTEIN AND OXALIPLATIN ON CANCER STEM CELLS IN ORAL SQUAMOUS CELL CARCINOMA: AN EXPERIMENTAL STUDY. EKB Journal Management System, 2018; 43(1): 117-123. doi: 10.21608/adjalexu.2018.57611

EFFECT OF GENISTEIN AND OXALIPLATIN ON CANCER STEM CELLS IN ORAL SQUAMOUS CELL CARCINOMA: AN EXPERIMENTAL STUDY

Alexandria Dental Journal
Article 21, Volume 43, Issue 1, April 2018, Page 117-123  XML PDF (816.01 K)
Document Type: Original Article
DOI: 10.21608/adjalexu.2018.57611
View on SCiNiTO View on SCiNiTO
Authors
Ahmed M. Hussein1; Sahar M. El-Sheikh2; Zeinab E. Darwish3; Khaled A. Hussein4; Ashraf I. Gaafar5
1Assistant Lecturer of Oral and Maxillofacial Pathology Department, Faculty of Oral and Dental Medicine, SVU, Kena, Egypt.
2Vice Dean of Student’s Affair, Professor of Oral Pathology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt
3Head of Oral Pathology Department, Professor of Oral Pathology, Faculty of Dentistry, Alexandria University, Alexandria, Egypt
4Professor of Oral Pathology, Department of Oral Pathology, Faculty of Dental Medicine, Al-Azhar University, Assiut, Egypt.
5Associate Professor of Oral Pathology, Department of Oral Pathology, Faculty of Dental Medicine, Al-Azhar University, Assiut, Egypt.
Abstract
INTRODUCTION: Squamous cell carcinoma is one of the malignant diseases that affect the oral cavity worldwide. One of the theories regarding oral carcinogenesis is that tumor growth is dependent on cancer stem cells. Markers specific for these cells as CD44 have been investigated in hope of developing a deeper understanding for their role in carcinogenesis. Genistein, as chemopreventive agent, has been shown to suppress the growth of several tumors. Oxaliplatin is a chemotherapeutic compound that did show a range of antitumor activity. OBJECTIVES: This research was carried out to study the effect of genistein, oxaliplatin either alone or in combination during experimentally DMBA induced hamster buccal pouch carcinogenesis using CD44 antibody as a marker. MATERIALS AND METHODS: A total of 100 young Syrian hamsters distributed into groups as follows: 4 normal animals examined for the histology of the normal pouch mucosa and 96 animals divided into; group I, as a control group, in which pouches were painted with a heavy mineral oil only; group II were painted with DMBA mixed in a heavy mineral oil. These animals were randomly divided into 4 subgroups as following: group IIA only painted with DMBA; group IIB where genistein was orally administrated; group IIC were injected with oxaliplatin; and group IID in which both genistein and oxaliplatin were given. RESULTS: Both genistein and oxaliplatin provided a significant reduction in carcinogenesis process of DMBA induced oral squamous cell carcinoma. Moreover, they provided a significant decrease in the proliferation and activity of cancer stem cells as measured by the CD44 antibody. CONCLUSIONS: Genistein provides a chemoprevention role and the oxaliplatin produces a chemotherapeutic effect during the process of carcinogenesis. The combined action of both agents was better than the effect of each agent alone.
Keywords
genistein; Oxaliplatin; Cancer stem cells; CD44
References
  1. Mignogna MD, Fedele S, Lo Russo L. The world cancer report and the burden of oral cancer. Eur J Cancer Prev. 2004;13:139-42.
  2. Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 2014;50:387-403.
  3. Nagini S, Kowshik J. The Hamster Buccal Pouch Model of Oral Carcinogenesis. Methods Mol Biol. 2016;1422:341-50.
  4. Suresh K, Manoharan S, Vijayaanand MA, Sugunadevi G. Chemopreventive and antioxidant efficacy of (6)- paradol in 7,12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis. Pharmacol Rep. 2010;62:1178-85.
  5. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23:7274-82.
  6. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 2005;26:495-502.
  7. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med. 2008;14:450-60.
  8. Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res. 2008;49:219-24.
  9. Karikas GA. Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J BUON. 2010;15:627-38.
  10. Rajkamal G, Suresh K, Sugunadevi G, Vijayaanand MA, Rajalingam K. Evaluation of chemopreventive effects of Thymoquinone on cell surface glycoconjugates and cytokeratin expression during DMBA induced hamster buccal pouch carcinogenesis. BMB Rep. 2010;43:664-9.
  11. Pugalendhi P, Manoharan S, Suresh K, Baskaran N. Genistein and daidzein, in combination, protect cellular integrity during 7,12-dimethylbenz[a]anthracene (DMBA) induced mammary carcinogenesis in SpragueDawley rats. N Afr J Tradit Complement Altern Med. 2011;8:91-7.
  12. Huang W, Wan C, Luo Q, Huang Z, Luo Q. Genisteininhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer. Int J Mol Sci. 2014;15:3432-43.
  13. Karikas GA. Chemoprevention molecular and biochemical mechanisms involved in cancer control and management. Heal Scien J. 2011;5:149-56.
  14. American Cancer Society. Chemotherapy drugs: how they work. Last Medical Review. 2015;1:1-17.
  15. Baker DE. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum. Rev Gastroenterol Disord. 2003;3:31-8.
  16. Hema K, Rao K, Devi HU, Priya N, Smitha T, Sheethal H. Immunohistochemical study of CD44s expression in oral squamous cell carcinoma-its correlation with prognostic parameters. J Oral Maxillofac Pathol. 2014;18:162-8.
  17. Ghaemi A, Soleimanjahi H, Razeghi S, Gorji A, Tabaraei A, Moradi A. Genistein induces a protective immunomodulatory effect in a mouse model of cervical cancer. Iran J Immunol. 2012;9:119-27.
  18. Pugalendhi P, Manoharan S, Panjamurthy K, Balakrishnan S, Nirmal MR. Antigenotoxic effect of genistein against 7,12-dimethylbenz[a]anthracene induced genotoxicity in bone marrow cells of female Wistar rats. Pharmacol Rep. 2009;61:296-303.
  19. Johnson TL, Lai MB, Lai JC, Bhushan A. Inhibition of cell proliferation and MAP kinase and Akt pathways in oral squamous cell carcinoma by genistein and biochanin A. Evid Based Complement Alternat Med. 2010;7:351-8.
  20. Myoung H, Hong SP, Yun PY, Lee JH, Kim MJ. Anticancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci. 2003;94:215–20.
  21. Yang Y, Zhou ZT, Ge JP. Effect of genistein on DMBA-induced oral carcinogenesis in hamster. Carcinogenesis. 2006;27:578-83.
  22. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, et al. Clinical and pharmackinetics study of oxaliplatin in colon cancer patients. J gastrointestin liver Dis. 2009;18:39-43.
  23. De Dosso S, Mazzucchelli L, Ghielmini M, Saletti P. Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori. 2009;95:378-81.
  24. Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, et al. Efficacy and safety analysis of oxaliplatin-based chemotherapy for advanced gastric cancer. Anticancer Res. 2017;37:2663-71.
  25. Shen Z, Xu L, Li J, Zhang N. Capilliposide C sensitizes esophageal squamous carcinoma cells to oxaliplatin by inducing apoptosis through the PI3K/Akt/mTOR pathway. Med Sci Monit. 2017;23:2096-103.
  26. Fakhrian K, Ordu AD, Haller B, Theisen J, Lordick F, Bisof V, et al. Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens. Strahlenther Onkol. 2014;190:987-92.
  27. Yang K, Zhao N, Zhao D, Chen D, Li Y. The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day. Drug Des Devel Ther. 2013;7:511-7.
  28. Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, et al. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett. 2009;278:201-9.
  29. Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, Sethi S, et al. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer. 2011;128:1240-50.
  30. Pintova S, Planutis K, Planutiene M, Holcombe RF. ME-143 is superior to genistein in suppression of WNT signaling in colon cancer cells. Anticancer Res. 2017;37:1647-53.
  31. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012;72:365-74.
  32. Paulis YW, Huijbers EJ, van der Schaft DW, Soetekouw PM, Pauwels P, Tjan-Heijnen VC, et al. CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget. 2015;6:19634-46.
  33. Rajarajan A, Stokes A, Bloor BK, Ceder R, Desai H, Grafström RC, et al. CD44 expression in oropharyngeal carcinoma tissues and cell lines. PLoS One. 2012;7:e28776.
  34. Margaritescu C, Pirici D, Simionescu C, Stepan A. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Rom J Morphol Embryol. 2011;52:985-93.
  35. Krump M, Ehrmann J. Differences in CD44s expression in HNSCC tumors of different areas within the oral cavity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:280-3.
  36. Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol. 2016;40-41:192-208.
  37. Sak K, Everaus H. Role of flavonoids in future anticancer therapy by eliminating the cancer stem cells. Curr Stem Cell Res Ther. 2015;10:271-82.
  38. Cao X, Ren K, Song Z, Li D, Quan M, Zheng Y, et al. 7-Difluoromethoxyl-5,4'-di-n-octyl genistein inhibits the stem-like characteristics of gastric cancer stem-like cells and reverses the phenotype of epithelialmesenchymal transition in gastric cancer cells. Oncol Rep. 2016;36:1157-65.
  39. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009;69:1951-7.
  40. Huang R, Wang G, Song Y, Tang Q, You Q, Liu Z, et al. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. Mol Med Rep. 2015;12:2417-24.
Statistics
Article View: 218
PDF Download: 396